Literature DB >> 23306854

In recurrent C. difficile, the CRP response to the primary C. difficile infection predicts whether the same strain or a different strain will cause a second infection.

Kangni Chen1, Stephanie d'Arc, Naveen Setty, Kathy Bamford, Neil Fairweather, Jonathan Tyrrell-Price.   

Abstract

BACKGROUND: Clostridium difficile is the leading cause of antibiotic-associated diarrhoea and is associated with an increase in morbidity and mortality. There is a wide variance in disease severity with some patients suffering a single, self-limiting episode of diarrhoea while others suffer more intractable problems with recurrent attacks or toxic dilatation. Numerous different C. difficile ribotypes exist, some of which are considered hypervirulent. The magnitude of toxin production alone is not sufficient to explain the varying virulence of these ribotypes, suggesting the involvement of other mechanisms.
METHODS: To test the same patient's response to infection with different C. difficile ribotypes, we reviewed 45 patients who suffered two episodes of C. difficile infection and determined by ribotyping and MLVA whether the second episode was due to the same strain or a different strain.
RESULTS: Patients harbouring a different strain had significantly higher C-reactive protein (CRP) responses on the first assessed infection (143 mg/L ± 20 vs. 55 ± 9.63, p = 0.0001) and a significantly lower CRP on reinfection (p = 0.048). Same strain patients had a non-significant increase in CRP response on second infection.
CONCLUSIONS: This suggests that the inflammatory response to C. difficile is determined by an interaction between host immunobiology, previous exposure and C. difficile strain.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23306854     DOI: 10.1007/s10620-012-2534-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

1.  Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea.

Authors:  F Barbut; A Richard; K Hamadi; V Chomette; B Burghoffer; J C Petit
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

2.  Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.

Authors:  Jost Langhorst; Sigrid Elsenbruch; Julia Koelzer; Andreas Rueffer; Andreas Michalsen; Gustav J Dobos
Journal:  Am J Gastroenterol       Date:  2007-10-04       Impact factor: 10.864

3.  PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes.

Authors:  S L Stubbs; J S Brazier; G L O'Neill; B I Duerden
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

4.  C-reactive protein is a useful predictor of metronidazole treatment failure in mild-to-moderate Clostridium difficile infection.

Authors:  Hugo A Farne; Natasha K Martin; Janice Main; Timothy Orchard; Jonathan Tyrrell-Price
Journal:  Eur J Gastroenterol Hepatol       Date:  2013-01       Impact factor: 2.566

5.  Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by clostridium difficile.

Authors:  Anna Wanahita; Elizabeth A Goldsmith; Daniel M Musher
Journal:  Clin Infect Dis       Date:  2002-05-23       Impact factor: 9.079

6.  Typing and subtyping of Clostridium difficile isolates by using multiple-locus variable-number tandem-repeat analysis.

Authors:  Renate J van den Berg; Inge Schaap; Kate E Templeton; Corné H W Klaassen; Ed J Kuijper
Journal:  J Clin Microbiol       Date:  2006-12-13       Impact factor: 5.948

7.  Recurrence of symptoms in Clostridium difficile infection--relapse or reinfection?

Authors:  M H Wilcox; W N Fawley; C D Settle; A Davidson
Journal:  J Hosp Infect       Date:  1998-02       Impact factor: 3.926

8.  Clostridium difficile infection in patients with unexplained leukocytosis.

Authors:  Anna Wanahita; Elizabeth A Goldsmith; Bernard J Marino; Daniel M Musher
Journal:  Am J Med       Date:  2003-11       Impact factor: 4.965

9.  Human antibody response to surface layer proteins in Clostridium difficile infection.

Authors:  Denise Drudy; Emanuela Calabi; Lorraine Kyne; Stavros Sougioultzis; Eoin Kelly; Neil Fairweather; Ciarán P Kelly
Journal:  FEMS Immunol Med Microbiol       Date:  2004-07-01

10.  Mortality and risk stratification in patients with Clostridium difficile-associated diarrhoea.

Authors:  S Bhangu; A Bhangu; P Nightingale; A Michael
Journal:  Colorectal Dis       Date:  2009-03-11       Impact factor: 3.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.